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Assessing and Treating Work- Related Asthma
Tracy Stoughton, MD, Michael Prematta, MD, and Timothy Craig, DO
Work- related asthma is asthma that is caused or exacerbated by exposures at work. it is the most common form of occupational 
lung disease in developed countries. it has important impacts on the health and well- being of the affected individual, as well as 
consequences for society because of unemployment issues and workers’ compensation claims. With ongoing exposure, occupational 
asthma can result in persistent airway hyperresponsiveness and, possibly, permanent disability for the individual. thus, it is important 
for the clinician to be able to diagnose this disorder as quickly and accurately as possible. the evaluation of a patient with work-
 related asthma can be extensive. it includes obtaining a consistent history, identifying the cause in the workplace, and confirming 
the diagnosis with objective tests. after a diagnosis has been made, treatment must sometimes go beyond the medications used for 
nonoccupational asthma and include interventions to minimize or completely remove the individual from exposure to the causal agent 
if he or she has  sensitizer- induced occupational asthma. in addition, once an individual has been identified with occupational asthma, 
steps should be taken to prevent the development of this disorder in other workers. the purpose of this article is to review the current 
literature and provide the clinician with a stepwise approach to the diagnosis and management of a patient with work- related asthma.
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occupations are consistently identified as having higher risk 
than others and include the wood industry, agriculture, food 
industry, painters, automobile industry, public administra-
tion (including police and firefighters), health services, and, 
in some studies, hairdressers.4,7–10
The effects of OA are numerous. In addition to the imme-
diate health consequences, many studies have demonstrated 
the persistence of asthma symptoms, bronchial hyperrespon-
siveness, and airway inflammation even after removal from 
the causal agent (Figure 1).11–14 A study performed by Yacoub 
and colleagues found evidence that individuals with OA may 
also be at higher risk for psychological effects, in particular, 
anxiety disorders and dysthymia.14 Financial concerns for 
the individual are significant as well, with the majority of 
employees having to find alternative jobs after their diag-
nosis (many reporting a reduction of income), and as many 
as 25 to 30% of patients remaining unemployed after diag-
nosis.11,15 Finally, the effects of OA can be felt in the use of 
health resources (physician and emergency department vis-
its), workers’ compensation claims, and company changes 
that are undertaken to reduce the harmful exposures to their 
workers.2,12
Because of the financial burden, health of the index case, 
risk to other workers with similar exposure, and prevalence of 
this condition, it becomes increasingly important for physi-
cians to have a systematic way of evaluating patients for OA. 
Once the diagnosis is made, physicians must treat the patient 
and also give recommendations for interventions to be done 
at work. This may even include mobilizing consultants such 
W ork- related asthma is defined as asthma that is ei-ther attributable to or exacerbated by workplace en-
vironmental exposures. It encompasses two separate but 
related clinical entities: occupational asthma (OA) and work-
 aggravated asthma (WAA).1 In both circumstances, the work 
environment contributes to the symptoms of asthma. How-
ever, OA is defined as asthma that is actually caused by the 
workplace, whereas WAA is classified as pre- existing asthma 
with symptoms aggravated by the work environment.1–3
OA has become increasingly important as it is now the 
most common occupational lung disorder in developed coun-
tries. Various studies have been performed to estimate the 
true prevalence of OA asthma in several countries. In Canada, 
estimated work- related asthma cases range from 42 / million / 
year for women to 79 / million / year for men.4 In the United 
States, it has been estimated that anywhere between 3 and 
29% of adult asthma can be attributed to occupational expo-
sures.5–7 A large study performed in Europe in 1999 estimated 
that 5 to 10% of asthma in young adults could be ascribed to 
their occupations.8 Throughout most of these studies, certain 
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acerbate pre- existing asthma. Rarely, they may also induce 
isolated late responses or atypical reactions.
LMW chemicals also can lead to OA by immunologic 
mechanisms, resulting in airway inflammation with eosino-
phils, lymphocytes, mast cells, and thickened reticular base-
ment membranes.3 However, although some LMW agents, 
such as platinum salts and trimellitic anhydride, cause OA 
via specific IgE antibodies similar to HMW antigens, other 
LMW agents, such as plicatic acid in red cedar and diisocya-
nates, do not consistently result in the production of specific 
IgE antibodies. These agents may cause a variety of results 
with specific inhalation challenges, including immediate and 
dual reactions, as well as late asthmatic or atypical reactions.3 
There are currently several hypotheses about the pathophysi-
ology of these apparently IgE- independent reactions, but fur-
ther research is required to delineate the true mechanism.3,16 
Regardless of the exact pathophysiology, all of these types 
of OA are similar in that the patients who are sensitized to 
these agents will have further exacerbation of their symp-
toms and airway inflammation if exposure continues and are 
likely to have persistence of airway hyperresponsiveness even 
after removal from the offending agent following prolonged 
 exposure.2
OA can also be mediated by a yet unknown immunologic 
process, and since previous exposure is not necessary, it is of-
ten thought to be an  irritant- induced mechanism. RADS is 
asthma in a previously healthy individual caused by a single 
high- level exposure to an airway irritant. According to the 
American College of Chest Physicians, the diagnosis of RADS 
should include the following: “(1) a documented absence of 
preceding respiratory complaints; (2) onset of symptoms af-
ter a single exposure incident or accident; (3) exposure to a 
as industrial hygienists to assess the workplace and advise on 
proper adaptations that can protect the workforce.
Methods
OVID and PubMed were searched using the terms occupa-
tional asthma, work- aggravated asthma,  irritant- induced 
asthma, and reactive airway dysfunction syndrome (RADS) 
alone and in combination with epidemiology, diagnosis, and 
treatment. Both primary literature and recent reviews were in-
cluded to create a document that can be used by the practic-
ing allergist to assess and treat patients who may have work-
 related asthma.
Classification of Work- Related Asthma
Work- related asthma can be triggered by different types of 
compounds and mediated by a variety of mechanisms. Spe-
cifically, OA can be immunologically mediated by both high- 
(HMW) and low- molecular- weight (LMW) substances and 
may also be non–immunologically mediated  irritant- induced 
asthma or RADS. WAA occurs in those with pre- existing 
asthma in response to a variety of different triggers found in 
the workplace, whereas OA is directly induced by workplace 
exposure.
HMW agents, animal and plant proteins, cause OA 
through the induction of specific IgE antibodies and the 
typical cascade of events that are seen in “allergic asthma”; 
however, specific IgE may be present even in those without 
asthma. The pathophysiology of this type of OA is similar to 
non- occupational allergic asthma.1,3 HMW substances can 
result in direct sensitization and thereby cause OA or can ex-
Figure 1. Percentage of workers with per-
sistent symptoms following avoidance. 
Adapted from Brant A et al.11
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MSDSs can sometimes be incomplete as they do not always 
give information on sensitizers if they are found in low con-
centrations, even if they can be harmful.21 With the patient’s 
consent, information can also be obtained from people in the 
workplace, such as the employer, management, and medical 
personnel. Some companies may also employ industrial hy-
giene specialists who are responsible for recognizing, measur-
ing, and controlling workplace exposures. If available, these 
personnel can assist in identifying agents that may be causing 
or playing a role in a patient’s work- related asthma.2,17 Finally, 
if feasible, a walk- through performed by the clinician may 
also be valuable in identifying possible sensitizers.17
Gather Clinical Evidence
When evaluating a patient for work- related asthma, obtaining 
a clinical history is the first step in gathering supportive evi-
dence. In addition to obtaining exposure risks as noted above, 
it is important to obtain a complete past medical history 
with emphasis on childhood respiratory symptoms, history 
of atopy, previous home and work exposures, and cigarette 
smoking.17,22 It is crucial to understand the patient’s current 
symptoms, as well as their progression, since many times 
OA begins with upper airway symptoms such as rhinorrhea, 
congestion, and sneezing and progresses to chest tightness, 
cough, wheezing, and dyspnea.2,17,22 In addition, any tempo-
ral relationship to their current profession, that is, initial on-
set of symptoms (which can vary from months to years from 
initial employment), worsening symptoms while at work, and 
improved symptoms while away from work, should be ascer-
tained (Figure 2).2,3,17 Unfortunately, even a history that ap-
pears to be consistent with OA is not sufficient to diagnose 
OA. Malo and colleagues demonstrated that the clinical his-
tory has a positive predictive value of only 63% but a negative 
predictive value of 83% when compared with specific inhala-
tion challenges.23 Thus, the clinical history is more useful in 
helping rule out OA than in ruling in OA.
In the initial diagnostic workup of OA, immunologic 
testing in the form of skin- prick testing, radioallergosor-
bent test (RAST), or  enzyme- linked immunosorbent assay 
can be considered.2 As mentioned above, many different 
mechanisms lead to the development of OA, and, unfortu-
nately, not all are consistently driven by specific IgE antibod-
ies, which makes it difficult to reliably diagnose all forms of 
OA via immunologic tests. In addition, these tests are often 
limited by commercial availability and a lack of standardized 
agents.3,24 Despite these limitations, skin- prick tests can be 
useful in the diagnosis of OA caused by HMW agents (eg, ani-
mal proteins, wheat). Thus, when available, skin- prick testing 
gas, smoke, fume, or vapor with irritant properties present 
in very high concentrations; (4) onset of symptoms within 
24 h after the exposure with persistence of symptoms for at 
least 3 months; (5) symptoms simulate asthma with cough, 
wheeze, and dyspnea; (6) presence of airflow obstruction on 
pulmonary function tests; (7) presence of nonspecific bron-
chial hyperresponsiveness; and (8) other pulmonary diseases 
ruled out.”17 RADS can be caused by many different agents, 
such as chlorine, diisocyanates, smoke inhalation, phosphoric 
acid, sulphuric acid, and ammonia.18,19 Of note, some of these 
agents can also be sensitizers. The proposed pathophysiology 
of RADS involves direct epithelial damage, with resultant 
neurogenic inflammation.3,18
Some researchers have proposed expanding the definition 
of RADS to include more than one  short- term high- level ex-
posure and onset of symptoms up to 7 days after exposure; 
others go even further to include chronic exposure to low 
levels of irritants. However, these suggestions have not been 
widely accepted as an expansion of the definition and would 
make it even more difficult to differentiate RADS from other 
causes of airway hyperresponsiveness.18,19
WAA is the final category of work- related asthma. In 
WAA, patients with known asthma can have exacerbations 
caused by inhalation of irritants at work (aerosols, dust, gases, 
fumes) or worsening symptoms caused by cold air exposure 
or exertion.2,20
Identify Exposures
When first interviewing a patient with suspected work- related 
asthma, it is important to identify exposures in the workplace 
that might be causing or contributing to their symptoms. It 
is necessary to understand their current job activities, with 
particular emphasis on processes that transfer materials, dis-
turb allergen reservoirs, and form new reaction products.17 
Clinicians should also get a sense of nearby processes and the 
“intensity of airborne exposures by asking about visible dust, 
odors, and mucous membrane irritation.”2 Specific inquiries 
should also be made about known triggers of asthma, includ-
ing cold air, exertion, pollens, animal dander, mould, fumes, 
cigarette smoke, vapours, and ambient air pollution.2,3
In addition to the patient interview, exposure risk can be 
assessed from other sources of information at the workplace 
itself. Material safety data sheets (MSDSs) can be a very useful 
source of information. The MSDSs list the name, manufac-
turer, and chemical composition of toxic agents in the work-
place and describe the potential health effects of these agents. 
In this way, they can be very useful for helping to identify po-
tential sensitizing agents.2,17 However, it should be noted that 
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ers have studied serial MC for the primary diagnosis of OA. 
To do this, MC is performed at the end of an extended work 
period, preferably within 24 hours of work, and then again at 
the end of an extended period (some suggest 3 weeks) of leave 
from work. A threefold or greater increase in the provoca-
tive concentration dose required to reduce forced expiratory 
volume in 1 second (FEV1) by 20%, while away from work, is 
considered to be consistent with OA.20,24 Unfortunately, not 
all researchers have found benefit in serial MC when com-
pared with serial peak expiratory flow (PEF) rates and specific 
challenge tests,29,30 so use of this test should generally be in 
conjunction with other clinical evidence.
Another method commonly used to evaluate OA is moni-
toring serial PEF rates in and out of the workplace. Patients 
should ideally monitor PEF every 2 hours while awake (three 
readings each time) for a period of 4 weeks—preferably 2 
weeks at work, if tolerated, and 2 or more weeks away from 
work.29,31 During this time period, patients should also keep a 
diary of their activities with specific details on working times 
and activities.31 As this regimen can create difficulties with 
compliance, some have recommended measurement of PEF 
less frequently during the day. If this is considered, measure-
ments should still be taken at least four times per day to pre-
serve sensitivity and specificity.32 The values are then sub-
mitted for analysis. Several different methods of analysis exist. 
Most commonly, values are plotted and visually examined 
is generally recommended in the workup of OA caused by 
these agents.17,25 With few exceptions, immunologic testing 
for LMW agents is more difficult since many of these agents 
do not consistently result in the production of specific IgE, 
and positive serum IgE can also be indicative of exposure 
but not necessarily disease.3 However, a study done on iso-
cyanates did show that a positive serum IgE, indicated by a 
RAST score of 3 or greater, was highly specific (100%) for the 
diagnosis of  isocyanate- induced OA. Therefore, its presence, 
along with a consistent clinical history, was diagnostic for 
 isocyanate- induced OA. Unfortunately, the sensitivity of this 
test was only 20%, so it cannot be reliably used to diagnose all 
cases of  isocyanate- induced OA.26
A second test that can be used in the workup of OA is 
the measurement of nonspecific bronchial hyperreactivity 
(NSBH), most commonly assessed through methacholine 
challenge (MC) tests, performed either serially or as a  single 
initial test. In a recent systematic review, use of a single NSBH 
test was found to have a pooled sensitivity of 79.3% and a 
specificity of 51.3% when compared with specific chamber 
challenge.27 Similar findings in other studies28 have led some 
to recommend checking MC as part of the initial workup of 
OA, essentially to help establish the diagnosis of asthma.24,27 
Then, after bronchial hyperreactivity has been confirmed, the 
physician can proceed with testing that actually links asthma 
to the exposures at work. On the other hand, some research-
Figure 2. Symptomatic presentation of 
occupational asthma. Adapted from Malo 
J- L et al.23
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for the diagnosis of OA. The exact procedure for a specific 
challenge depends on the type of agent being investigated. 
Some agents can be safely aerosolized and delivered via nebu-
lizer for specific challenge testing. For these agents, concen-
tration of the agent can be increased on different testing days 
until a decrease in FEV1 by 20% is achieved, which is consid-
ered a positive provocative challenge.25 In the assessment of 
OA caused by vapours, fumes, or gases, testing may require a 
challenge chamber. A challenge chamber is a room or a small, 
enclosed space where the suspected agent is delivered into the 
atmosphere at precise concentrations.25,37 Care is taken not to 
exceed the concentration of the agent that would be encoun-
tered at work or a concentration that could be considered an 
irritant.25,37 Finally, for some agents, innovative ways must be 
designed to safely test for sensitization.
The advantage of specific inhalation challenge testing is 
that it can provide a definitive answer, both confirming the 
diagnosis of OA and identifying the causal agent. Unfortu-
nately, there are multiple drawbacks to specific inhalation 
testing. There is a lack of standardization for this type of test-
ing. Therefore, it must be performed in specialized laborato-
ries with the appropriate equipment and a general familiarity 
with effective, safe testing doses.37 False- positive results can 
occur in patients who have unstable asthma or are exposed 
to  irritant levels of the agent.20 For patients who are exposed to 
multiple potential sensitizers, testing may have to be done to 
a number of different agents to achieve a diagnosis.37 Even if 
multiple specific challenges are performed,  false- negative re-
sults can still occur if testing with the correct agent is not per-
formed27 or if the exposure during testing is not of adequate 
concentration or duration.20 Given that late reactions can also 
occur, pulmonary function monitoring must continue for at 
least 6 hours, if not longer, after the exposure has taken place 
to avoid missing the diagnosis in those with isolated late re-
actions.20,37 Lastly, some have advocated the use ofMC tests 
on the day before and after specific inhalation testing to in-
crease the sensitivity of this test. Unfortunately, there are 
only a few large academic centres in Canada and the United 
States where specific challenges can be performed successfully 
and safely.
In summary, none of the available objective tests are per-
fect for diagnosing OA. As a result, cases should be consid-
ered on an individual basis and tests should be ordered ac-
cordingly, with consideration of the benefits and drawbacks 
of each. Often a combination of tests performed in a stepwise 
approach, along with a consistent history, is most helpful in 
the diagnosis of OA. Even though specific inhalation chal-
lenges are considered the gold standard, they are difficult to 
perform and do not necessarily provide a definitive diagno-
sis. For these reasons, the current general recommendation 
for variations between PEF measurements at and away from 
work. Visual examination of serial PEF by experts produces a 
sensitivity and a specificity between 73 and 86% and 74 and 
100%, respectively, when compared with specific chamber 
challenge.29,30,33 In addition, a computer program, OASYS- 2 
(Oasys Research Group, Midland Thoracic Society, UK), has 
been designed to analyze PEF variations without the use of 
graphs or expert interpretation. This computer program has 
been found to have a sensitivity of 69% and a specificity of 
94% in people with a diagnosis of OA made independently of 
serial PEF.34 Of note, although some have hypothesized that 
serial measurement of FEV1 would be superior to serial PEF, 
a study performed by Leroyer and colleagues did not find this 
to be true; in fact, this study showed that analysis of serial PEF 
measurements was more sensitive and specific than analysis 
of serial FEV1.33 This study also demonstrated superior results 
using the best of three values for analysis as opposed to the 
common method of using the best of two reproducible values.
PEF monitoring is popular owing to the fact that it has 
relatively high sensitivity and specificity, is easy to perform, 
and is inexpensive. It also gives measurements over time, in-
creasing the likelihood of including late reactions and pro-
longed recoveries. Unfortunately, despite these benefits, this 
method also has several drawbacks: it is a time- consuming 
test and thus creates difficulties with patient compliance; it 
is effort dependent, and since it is an unsupervised test, the 
patient must be relied on to use best effort with each measure-
ment; it can underestimate changes in airway calibre; it does 
not identify the causal agent but just a relationship between 
work and changes in PEF; and finally, concern arises regard-
ing falsification of records, especially when compensation is 
at stake.17,31 Fortunately, if falsification is a serious concern, 
computerized peak flow meters are available and can be used 
to eliminate the concern of writing down false numbers.17,31 
However, these meters still cannot evaluate patient effort.
Another test that can be used in the objective evaluation 
of OA is analyzing the number of eosinophils in induced spu-
tum. In this form of testing, sputum production is induced 
using increasing concentrations of inhaled hypertonic sa-
line during periods at and away from work.35,36 It has been 
found that patients with OA have higher numbers of sputum 
eosinophils and eosinophil cation protein during periods at 
work compared with periods away from work.36 In a study 
performed by Girard and colleagues, an increase in sputum 
eosinophils of 2% was found to add to the sensitivity and 
specificity of PEF monitoring by 8.2% and 18%, respectively.35 
Thus, it appears that the use of induced sputum may be a valu-
able adjunct to other tests in the assessment of OA.
Finally, OA can be assessed with the use of specific inhala-
tion challenge testing, which is considered the gold standard 
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that they are no longer exposed to the agent.2,17,20 Finally, a 
respirator for personal protection can also be provided to pa-
tients with work- related asthma, particularly for  short- term 
exposures. When used, it must be ensured that the respira-
tor is the correct type and is fitted properly and that the pa-
tient is educated on how to wear and remove it.38 The long-
 term use of respirators in a patient with  sensitizer- induced 
OA is generally not recommended as the patient may still 
continue to be exposed to small amounts of the agent, and 
even small amounts can trigger symptoms. For patients with 
 irritant- induced asthma, the use of a respirator, on a periodic 
basis, may be adequate for control of their symptoms.2,17,20
After appropriate interventions have been taken to treat 
work- related asthma, it is important to continue monitoring 
the patient and exposed coworkers. Continued monitoring 
can help the clinician and the patient determine whether the 
accommodations are effective.2 This is particularly important 
in  sensitizer- induced OA, for which fatalities have been re-
ported in patients who remain exposed. As mentioned previ-
ously, even patients who have been removed from exposure to 
the sensitizing agent or irritant can have persistence of bron-
chial hyperresponsiveness. Thus, it is important to continue 
monitoring these patients to ensure adequate symptom con-
trol. Finally, it is also important for the clinician to consider 
the psychological and financial impacts that OA may have on 
the patient. As anxiety and dysthymia have both been linked 
to OA, screening for these conditions can be an important 
adjunct to the patient’s overall care.14 Clinicians caring for pa-
tients with OA should also be prepared to participate in work-
ers’ compensation claims and disability if necessary to provide 
the objective clinical evidence that was used for the diagnosis 
of OA and advocate for their patient to receive appropriate 
compensation if applicable.3
Prevention and Surveillance
Outcomes in  sensitizer- induced OA are improved when pa-
tients have a shorter duration of symptoms prior to diagno-
sis, nearly normal lung function at the time of diagnosis, and 
is that specific inhalation challenges are not essential for the 
diagnosis of OA. However, they should be considered in cases 
in which the diagnosis of OA cannot be accomplished with 
other tests.20
Interventions
Pharmacologic treatment for work- related asthma does not 
differ from that for non- OA.17 Inhaled corticosteroids are 
used for chronic therapy and acute symptoms treated with 
bronchodilators. In addition, patients should be educated 
about their asthma, taught to recognize and treat symptoms 
appropriately, and have asthma action plans. Patients should 
also avoid non- occupational exposures that exacerbate their 
asthma symptoms, such as smoking and allergen exposure if 
applicable.20
Unfortunately, since work- related asthma is caused or 
worsened by exposures encountered at work, interventions 
have to go beyond those normally taken for non- OA. Patients 
must be counselled about their ongoing risks if exposure to 
the offending agent continues. For OA induced by sensitizing 
agents, the prognosis is worsened by longer periods of expo-
sure to the agent. Even minute exposures can induce symp-
toms, and patients can retain their sensitivity to these agents 
even if they have been unexposed and asymptomatic for pro-
longed periods.13 Thus, the goal for patients with OA induced 
by sensitizing agents is to be removed from all exposures to 
the offending agent.17,20 They should also avoid reexposure in 
the future.13 For patients who have  irritant- induced or wors-
ened asthma, either RADS or WAA, it may not be necessary to 
completely avoid all exposure to the offending agent but rather 
to ensure that high levels of the agent are not  encountered.17,20
Several different steps can be taken at the workplace to 
accommodate for patients with work- related asthma. Compa-
nies can replace the identified sensitizing agent with another 
less sensitizing or toxic agent. Processes can be enclosed, or 
effective local ventilation systems can be established. If these 
are not practical options, the patient with  sensitizer- induced 
OA can be transferred to a different job or location to ensure 
Table 1. Essential Literature for the Practicing Allergist 
Article Name Author(s) Journal
“Canadian Thoracic Society Guidelines for 
Occupational Asthma”
Susan M. Tarlo, Louis- Philippe Boulet, 
André Cartier, et al
Can Respir J 1998;5:289–300
“Assessment of Asthma in the Workplace. ACCP 
Consensus Statement”
M. Chan- Yeung Chest 1995;108:1084–117
“Guidelines for Assessing and Managing Asthma 
Risk at Work, School, and Recreation”
American Thoracic Society Am J Respir Crit Care Med 2004; 
169:873–81
“Evidence Based Guidelines for the Prevention, 
Identification, and Management of 
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Taylor, et al
Occup Environ Med 2005;62:290–9
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early removal from the causative agent. Early identification 
and intervention are therefore crucial to improved medical 
and financial outcomes for the patient. As a result, recom-
mendations have been made to help employers reduce the 
number of workers who develop OA and identify those who 
are affected as early as possible. In professions in which the 
risk of OA is high, these recommendations include remov-
ing or reducing exposures to known sensitizing agents for all 
workers and instituting surveillance programs in which em-
ployees at risk for work- related asthma are screened by health 
and safety personnel with questionnaires, pulmonary func-
tion tests, and immunologic tests, as appropriate.3,20,38 More 
frequent monitoring should be performed for workers who 
have underlying asthma or develop rhinitis.38 In addition, 
patients who develop positive immunologic reactions should 
also undergo more frequent monitoring and consider reduc-
ing exposures to the indicated agent at the time the sensitivity 
is discovered.20
Summary
In conclusion, work- related asthma is a common disorder that 
is increasing in prevalence and has important medical, so-
cial, and economic consequences. The causes of work- related 
asthma are vast and mediated by a variety of immunologic 
and non- immunologic mechanisms. As a result, the diagno-
sis of work- related asthma can be a complicated and time-
 consuming task. In general, physicians should take a stepwise 
approach, starting with a comprehensive medical history and 
evaluation of exposures, and then proceed with objective tests 
to support the diagnosis. No one test is the definitive diagnos-
tic test for work- related asthma, so a combination of tests is 
usually indicated. If the diagnosis of work- related asthma is 
established, steps must be taken to ensure adequate removal 
or minimization of the causal agent from the patient’s work 
environment. As OA may be a progressive disease with wors-
ening prognosis as exposure continues, early diagnosis and 
intervention are imperative for the patient. Importantly, each 
worker who develops OA should be considered an index case, 
and other exposed workers should be assessed to reduce the 
possibility that they develop OA. Optimally, prevention strat-
egies and surveillance programs in the workplace should pre-
vent the development and progression of OA; however, at the 
present time, these programs are inadequate to completely 
prevent  occupation- induced diseases. The practicing allergist 
is encouraged to have the resources listed in Table 1 available 
to use as a reference in assessing a patient with work-related 
asthma.
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